WuXi Biologics (Cayman) Inc. (02269.HK) Latest Company News

Sep 16, 2026, 13:11 UTC
WuXi Biologics signed an agreement to land a commercial high-end manufacturing platform project in Wuxi, including new biologic drug production lines and supporting process development laboratories.
Source:
- finance.sina.cn
Sep 14, 2026, 08:12 UTC
Hong Kong stocks closed higher on September 14, 2026, with the Hang Seng Index up 111 points or 0.5% at 24,917, while the Hang Seng Tech Index slipped 2 points or 0.1% to 4,317 and the China Enterprises Index rose 38 points or 0.5% to 8,284 on turnover of HK$192.625 billion.
Source:
- aastocks.com
- aastocks.com
Sep 14, 2026, 04:12 UTC
Hong Kong stocks closed the morning session higher on September 14, 2026, with the Hang Seng Index up 87 points at 24,893 and the Hang Seng Tech Index up 7 points at 4,327.
Source:
- aastocks.com
- aastocks.com
Aug 27, 2026, 08:31 UTC
WuXi Biologics management raised its full-year 2026 revenue growth guidance to 20%-23% year-over-year on a constant currency basis, up from the previous 16%-20% guidance.
Source:
- aastocks.com
Aug 25, 2026, 09:56 UTC
WuXi Biologics reported first-half results with revenue up 18.4% year-on-year to RMB 11.787 billion, gross profit up 28.1% to RMB 5.448 billion, and net profit up 5.8% to RMB 2.916 billion.
Source:
Aug 6, 2026, 23:32 UTC
Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.
Source:
- aastocks.com
- aastocks.com
Jul 4, 2026, 11:52 UTC
Hong Kong-listed companies, led by Tencent Holdings, AIA Group, and Xiaomi Corporation, have conducted share buybacks totaling over 900 billion Hong Kong dollars year-to-date, with June 2026 reaching a monthly record of over 300 billion Hong Kong dollars.
Source:
- wap.eastmoney.com
- finance.sina.cn
Jun 18, 2026, 05:00 UTC
WuXi Biologics' Suzhou Biosafety Testing Center received its fourth EMA GMP certification, enabling 19 commercial products for the European market.
Source:
- gurufocus.com
Jun 5, 2026, 02:45 UTC
WuXi Biologics completed the topping-out of a drug product facility at its Singapore CRDMO Hub.
Source:
- prnewswire.com
- gurufocus.com

02269.HK

WuXi Biologics signed an agreement to land a commercial high-end manufacturing platform project in Wuxi, including new biologic drug production lines and supporting process development laboratories.

Hong Kong stocks closed higher on September 14, 2026, with the Hang Seng Index up 111 points or 0.5% at 24,917, while the Hang Seng Tech Index slipped 2 points or 0.1% to 4,317 and the China Enterprises Index rose 38 points or 0.5% to 8,284 on turnover of HK$192.625 billion.

Hong Kong stocks closed the morning session higher on September 14, 2026, with the Hang Seng Index up 87 points at 24,893 and the Hang Seng Tech Index up 7 points at 4,327.

WuXi Biologics management raised its full-year 2026 revenue growth guidance to 20%-23% year-over-year on a constant currency basis, up from the previous 16%-20% guidance.

WuXi Biologics reported first-half results with revenue up 18.4% year-on-year to RMB 11.787 billion, gross profit up 28.1% to RMB 5.448 billion, and net profit up 5.8% to RMB 2.916 billion.

Transcenta Holding announced the sale of its CDMO assets to WuXi Biologics for RMB 190 million, excluding intellectual property related to its candidate drug pipeline and core biomanufacturing platform.

Hong Kong-listed companies, led by Tencent Holdings, AIA Group, and Xiaomi Corporation, have conducted share buybacks totaling over 900 billion Hong Kong dollars year-to-date, with June 2026 reaching a monthly record of over 300 billion Hong Kong dollars.

WuXi Biologics' Suzhou Biosafety Testing Center received its fourth EMA GMP certification, enabling 19 commercial products for the European market.

WuXi Biologics completed the topping-out of a drug product facility at its Singapore CRDMO Hub.